verse pregnancy outcomes has been added to this difficult risk-benefit equation. This review analyzes 14 studies that looked at the relationship between drinking water DBPs and 5 studies of other common chlorinated compounds (primarily trichloroethylene [TCE] and perchloroethylene [PCE] ) and low birth weight, spontaneous abortion, fetal death, and various birth defects. These studies were heterogeneous in their exposure measures and definitions of outcome and were therefore subjected to a qualitative rather than quantitative analysis. The most prominent bias noted in these studies was misclassification of exposure and outcome, either of which would tend to underestimate any existing risks. The authors judged the evidence for low birth weight, neural tube defects, and spontaneous abortions associated with DBPs to be moderately strong. Fewer studies were available for the other solvents, but TCE was judged to warrant follow-up for possible excess neural tube defects, oral clefts, cardiac defects, and choanal atresia given the existing literature.
COMMENTARY
Better than 80% of households are on public water systems, and a large proportion of these use chlorine for disinfection. Chlorination has been an exceedingly important measure to prevent waterborne disease over the last century, but the discovery that this benefit may have unwanted side effects has prompted increasing research into this problem. The increased risk of cancer is now generally accepted as one such problem. Now, emerging research also implicates reproductive effects. Given the extremely high prevalence of exposure (both to the DBPs and to TCE and PCE), even fairly small risks could produce an appreciable population burden. Moreover, there is a special public sensitivity to adverse reproductive outcomes that make this topic highly charged. The data on cancer and reproductive effects are already producing new rules that will govern limits on DBPs likely to result in major changes in water treatment technology and practice, perhaps with a rapid changeover to ozonation or ultraviolet light as a primary disinfectant in the 21st century. This article is an excellent review of a challenging and important area of frequent concern to patients. Ko G, First M, Burge H. The characterization of upper-room ultraviolet germicidal irradiation in inactivating airborne microorganisms. Environ Health Perspect. 2002; 110:95-101 .
SUMMARY
Upper-room ultraviolet germicidal irradiation (UVGI) with 254 nm (UV-C) radiation has been recommended as a means to reduce or prevent transmission of airborne microorganisms in high-risk settings such as health care institutions. An organism of particular interest is Mycobacterium tuberculosis.
1 The efficacy of such units needs to be assessed, and this is the latest and one of the most elaborate attempts to do so. Using an experimental room and a generator to produce controlled aerosols of M. bovis and Serratia marcescans (the former known to be roughly equal in UV sensitivity as M. tuberculosis), a variety of factors that affect UVGI effectiveness was investigated, including number of air changes per hour, UV dose, use of mixing fans with the device, relative humidity, and room temperature. Since suspending medium for the aerosols is likely important to survival, 10% fetal calf serum was used to simulate human saliva. Effectiveness was in the 60% to 80% range for either organism, but there was significant variation with temperature, air change, and other environmental factors.
COMMENTARY
While use of UVGI units has been proposed primarily for nosocomial and health care facility infection problems, it is likely only a matter of time before they are marketed aggressively as antibioterrorism devices. This article demonstrates that, while effective to some extent, UVGI is not a panacea, and its efficacy is affected by a variety of factors that can be difficult to control. At best, it is an adjunct to other practices. Moreover, UV sources are low-pressure mercury vapor lamps, and thus they can present a hazard for maintenance and disposal and a danger of UV exposure if they are not properly deployed. 
REFERENCE

COMMENTARY
A safe and effective hepatitis B vaccine has been available since 1982. At that time, it was first recommended for high-risk individuals. This strategy was tremendously effective for health care workers. Currently, the incidence of hepatitis B infection among health care workers is lower than that of the general population. However, immunizing individuals at high risk for hepatitis B acquisition through either drug use or sexual contact was not nearly as effective. In response to the inability to vaccinate those at high risk, a comprehensive immunization strategy of universal childhood vaccination was adopted in 1991. This will eventually lead to an immune population and, ideally, the eradication of hepatitis B. However, for the next several decades, high-risk adults are still becoming infected in large numbers. During the past two decades, an estimated 150,000 to 450,000 people have been infected each year, although that has decreased recently.
The Goldstein study was conducted in four sentinel counties, none of them known to have very high rates of injection drug use. For populations with higher rates of injection drug use, the proportion of high-risk persons that undergo incarceration may be even greater. This underscores the potential of implementing routine hepatitis B vaccination of all prisoners. In spite of the fact that hepatitis B vaccination has been shown to be cost-effective, the most significant obstacle to vaccinating high-risk individuals, particularly in correctional institutions, has been lack of funding for vaccine. This is clearly demonstrated in the article by Charuvastra et al., in which most state correctional facilities and the Federal Bureau of Prisons were found not to provide routine hepatitis B vaccination, but stated they would if vaccine were available without cost. It is time for policymakers and the federal and state governments to begin funding routine hepatitis B vaccination for all inmates. 
SUMMARY
Kirkland et al.'s study enrolled 108 antiretroviral-naive incarcerated individuals infected with human immunodeficiency virus (HIV), utilized a compact 4-tablet/day antiretroviral regimen administered twice daily under directly observed treatment conditions in the incarcerated setting. At 24 weeks, 85% of patients achieved HIV RNA level less than 400 copies per milliliter, and 75% had less than 50 copies per milliliter. The overall adherence to prescribed doses was 94% for patients who remained enrolled in the study.
Mitty et al.'s article describes the principle of directly observed therapy (DOT), which has its roots in tuberculosis (TB) treatment; it has dramatically improved TB cure rates in hard-to-reach populations and has become the standard of care. The similarities and differences in using DOT for TB and HIV are discussed. The authors also describe several successful pilot programs in prisoners (including the above-noted article of Kirkland et al.) and in the community in Haiti, Florida, and Rhode Island.
COMMENTARY
More than 90% of prescribed antiretroviral doses are needed for highly active antiretroviral therapy (HAART) to be effective and to avoid the development of resistant viral strains. Many HIV-infected persons that become incarcerated have tremendous difficulty adhering to antiretroviral therapy. These people often have comorbid conditions that contribute to their difficulty with adherence, including addiction, mental illness, and social problems.
The report by Kirkland et al. documents that, among incarcerated populations, a program of directly observed therapy for HIV can be effective and achieve virologic outcomes comparable to the best study populations outside prison. This is encouraging and sheds some light on a potential strategy for control of HIV in this population. The larger challenge is to extend these results beyond the incarcerated population when individuals are released to the community.
The report by Mitty et al. describes how the DOT approach can be applied to HIV and would be ideal for persons transitioning out of the incarcerated setting. In addition to controlling HIV replication, with reduced risk of development of viral resistance, this promising strategy may also address the need for enhanced linkage to medical care and substance abuse, mental health, and social services. DOT for incarcerated persons with HIV should be thoroughly explored and expanded to include the postincarceration period. 
SUMMARY
In an effort to demonstrate the potentially toxic effects of antiretroviral therapy on mitochondrial DNA content, these investigators used a real-time polymerase chain reaction (PCR) assay to quantify the relative mitochondrial DNA depletion of peripheral blood in relation to its nuclear DNA content. They sampled venous blood from three groups of individuals (all male) in this comparative trial: 24 controls not infected with human immunodeficiency virus (HIV); 47 HIV-infected, asymptomatic patients who had never been treated with antiretroviral drugs; and 8 HIV-infected patients with symptomatic hyperlactatemia who were receiving treatment with antiretroviral drugs. The last group manifested a spectrum of progressive clinical symptoms associated with elevated lactate levels and were receiving various combinations of highly active antiretroviral therapy (HAART) medications, each of which included the nucleoside analogue stavudine. These 8 patients were studied before, during, and after discontinuation of antiretroviral therapy.
Those patients with symptomatic hyperlactatemia showed marked reductions in the ratios of mitochondrial to nuclear DNA, which during therapy, averaged 68% lower than those of non-HIV-infected controls and 43% lower than those of HIV-infected asymptomatic patients never treated with antiretroviral drugs. The decline in mitochondrial DNA appeared to precede increases in venous lactate levels.
Discontinuation of antiretroviral therapy resulted in a statistically significant increase in the ratio of mitochondrial to nuclear DNA (P = .02). The maximal time before lactate levels returned to normal in those patients who discontinued therapy ranged from 4 to 28 weeks.
COMMENTARY
As clinical experience with combination antiretroviral therapy continues to grow, our knowledge of the types of both acute and long-term toxicities associated with HAART is expanding at a similar rate. The potentially damaging effects of antiretroviral therapy, particularly nucleoside analogues, on mitochondrial function is one such area that is becomingly increasingly well characterized and has been associated with a wide spectrum of clinical symptoms. Nucleoside analogues presumably induce their toxic effects on mitochondria by inhibiting the human DNA polymerase. The known toxic effects of continued treatment with these agents can range from increased serum lactate levels to potentially fatal lactic acidosis. Unfortunately, in the absence of a safe and convenient means of sampling affected tissues other than through relatively invasive procedures such as muscle and liver biopsies, the diagnosis of this condition can often be confused with other syndromes and is often empiric. For this reason, a rapid, noninvasive assay involving sampling of peripheral blood would represent a major advance in diagnosis.
The present study, which demonstrates a depletion in mitochondrial DNA levels relative to genomic DNA, presents some very promising data in this regard. Interpretation of the results is somewhat limited by the relatively small number of patients studied and the fact that only symptomatic patients with hyperlactatemia on HAART were studied; the study also raises obvious questions about the potential reproducibility of the assay in other hands. In addition, a recent study 1 of 10 control and 14 HIV-infected patients either on nucleoside reverse transcriptase inhibitor treatment with lipoatrophy or naive to all antiretrovirals found results that conflict with these data (i.e., no depletion of mitochondrial DNA was found). Nonetheless, these preliminary findings, if reproducible in larger numbers of patients and in different settings, are intriguing and augur the possibility that a better, safer means of diagnosing this potentially life-threatening condition might soon be available. 
SUMMARY
ACTG Study 364 was a randomized, multicenter, partially double-blind three-arm trial in 195 nucleoside-experienced HIV-infected patients; the study compared the relative benefits of adding either a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or both to a backbone of nucleoside analogue therapy. Patients breaking through nucleoside analogue treatment with a plasma HIV-1 RNA level of at least 500 copies per milliliter were randomly assigned to receive treatment with either the NNRTI efavirenz at 600 mg every day, the PI nelfinavir at 750 mg three times a day, or the combination of these two agents at these same doses. Depending on which agents the patients had received prestudy, efavirenz and/or nelfinavir were added to an open-label nucleoside analogue regimen containing at least one new drug and consisting of either didanosine 200 mg twice daily plus lamivudine 150 mg twice daily, didanosine 200 mg twice daily plus stavudine 40 mg twice daily, or stavudine 40 mg twice daily plus lamivudine 150 mg twice daily. The primary and secondary end points of the trial were the comparative changes in viral load levels at weeks 16 and at weeks 40 and 48, respectively, compared to baseline. At weeks 16 and weeks 40-48, respectively, the proportion of patients who achieved viral load levels of under 500 copies per milliliter were 81% and 74% for recipients of efavirenz plus nelfinavir, 69% and 60% for recipients of efavirenz, and 64% and 35% for patients receiving nelfinavir. Triple-drug therapy with efavirenz induced greater long-term virologic suppression than did treatment with nelfinavir. Predictors of long-term virologic suppression by multivariate analysis in this trial included the baseline viral load, the addition of lamivudine as a new NRTI, and assignment to combination NNRTI/PI therapy.
COMMENTARY
Despite the current availability of 16 different single licensed antiretroviral medications from which to select, even today the choice of the most appropriate second-line therapy in patients who fail their initial regimens is not necessarily either straightforward or obvious to many clinicians. The desire to avoid overlapping patterns of drug resistance with the current regimen, the need to minimize both acute and long-term toxicities of available agents while optimizing antiviral potency, the importance of selecting patient-friendly schedules of drug administration that enhance adherence, and the desire to reserve some agents for an eventual third-line or salvage strategy all contribute to uncertainty in the decision regarding the most appropriate regimen to which to switch. In this interesting 1997 study that evaluated three different switch regimens in patients who were failing their initial treatments with nucleoside analogue therapy alone, a second-line regimen involving addition of an NNRTI to two NRTIs was compared to that involving addition of either a single PI or a combination of an NNRTI with a PI. Not surprisingly, the quadruple-drug regimen achieved the best viral suppression both short term (16 weeks) and long term (40-48 weeks). Perhaps more surprising was the fact that the regimen containing the potent NNRTI (efavirenz) was the second-best performer in this regard. These findings would seem to bolster other data that suggest that, when possible, the choice of regimens involving addition of drugs from two new classes is likely to be superior to those involving addition of a single new class. However, when only a single new drug class can be used, the preference should be to select the most potent agent available. Obvious limitations of the study are that it was initiated in the early HAART era when fewer patients had been exposed to more than dual NRTIs as their initial regimens, it involved comparison of the most potent licensed NNRTI with a somewhat less potent licensed PI, and the virologic analysis was only carried out to 48 weeks so that true long-term outcomes were not available. 
SUMMARY
To determine the practicality and utility of a concentration-controlled approach to administering antiretroviral medications, these investigators undertook a randomized, open-label trial of this approach versus conventional fixed-dose therapy. Forty antiretroviral-naive HIVinfected patients with baseline plasma RNA levels greater than 5,000 copies per milliliter were started on zidovudine 300 mg twice daily, lamivudine 150 mg twice daily, and indinavir 800 mg twice daily; after 2 weeks, these individuals were randomly assigned either to continue HAART at these doses (n = 19) or to undergo dose modification based on pharmacokinetic assessments (n = 21). Beginning at week 4, patients in the concentration-controlled arm underwent dose modification to achieve target concentrations of zidovudine 0.17 mg/L or greater, lamivudine 0.40 mg/L or greater, and indinavir 0.13 mg/L or greater. End points of the trial were the proportion of patients achieving desired drug concentrations at a week 28 assessment, the proportion with plasma virus below 50 copies per milliliter at week 52, and the relative tolerability of each approach.
Based on repeat pharmacokinetics at week 28, the proportion of patients assigned to the concentration-controlled arm versus the conventional therapy arm who achieved the target concentrations for the three drugs were, respectively, zidovudine 100% versus 53%, lamivudine 100% versus 65%, and indinavir 88% versus 18%. Of the 16 patients in the concentrationcontrolled arm, 15 versus only 9/17 patients in the conventional treatment arm achieved viral loads less than 50 copies per milliliter at week 52. No differences in drug-related adverse events or laboratory abnormalities were noted between the two arms over the course of the study.
COMMENTARY
Despite the unprecedented ability to suppress viral replication and reverse CD4 cell declines afforded by conventional HAART therapy, longer term experience with these drugs has revealed rates of virologic failure often greater than those observed in initial clinical trials. While there can be, and undoubtedly are, several reasons for the discrepancies between clinical trial results and "real world" outcomes, few investigators have explored the potential failure of the conventional fixed-dose approach to treatment to achieve optimal levels of viral suppression in all patients. Rather, declining levels of drug adherence over time, unanticipated drug-drug interactions leading to altered drug metabolism, emerging viral resistance, and similar reasons have usually been invoked to account for the observed failure of HAART over time.
In this intriguing, open-label study of conventional versus concentration-controlled dosing, Fletcher et al. demonstrate that a surprising percentage of patients fail to achieve desired target concentrations of NRTIs or PIs when assigned to standard doses. As a consequence, they may fail to achieve viral suppression with the same rate of success as those patients whose drug doses are individually adjusted based on early pharmacokinetic analysis. Moreover, achieving and maintaining drug concentrations in the optimal suppressive range does not appear to be associated with any higher degree of drug-related side effects than conventional dosing. While preliminary, these findings suggest that, when feasible, individualized drug dosing on the basis of pharmacokinetic sampling may be one means of ensuring better virologic outcomes over the long term.
